TERN

TERN

USD

Terns Pharmaceuticals Inc. Common Stock

$17.430+1.930 (12.452%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$15.500

الأعلى

$18.740

الأدنى

$15.500

الحجم

4.37M

أساسيات الشركة

القيمة السوقية

1.5B

الصناعة

التكنولوجيا الحيوية

البلد

United States

إحصاءات التداول

متوسط الحجم

1.85M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $1.865الحالي $17.430الأعلى $18.74

أخبار ذات صلة

Analyst Upgrades

Truist Securities Reiterates Buy on Terns Pharma, Raises Price Target to $28

Truist Securities analyst Srikripa Devarakonda reiterates Terns Pharma with a Buy and raises the price target from $20 to $28.

عرض المزيد
Truist Securities Reiterates Buy on Terns Pharma, Raises Price Target to $28
Analyst Upgrades

BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $22

BMO Capital analyst Etzer Darout maintains Terns Pharma with a Outperform and raises the price target from $15 to $22.

عرض المزيد
BMO Capital Maintains Outperform on Terns Pharma, Raises Price Target to $22
Analyst Upgrades

Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $27

Barclays analyst Etzer Darout maintains Terns Pharma with a Overweight and raises the price target from $14 to $27.

عرض المزيد
Barclays Maintains Overweight on Terns Pharma, Raises Price Target to $27
Analyst Upgrades

HC Wainwright & Co. Upgrades Terns Pharma to Buy, Announces $20 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Terns Pharma from Neutral to Buy and announces $20 price target.

عرض المزيد
HC Wainwright & Co. Upgrades Terns Pharma to Buy, Announces $20 Price Target
Analyst Upgrades

William Blair Upgrades Terns Pharma to Outperform

William Blair analyst Andy Hsieh upgrades Terns Pharma from Market Perform to Outperform.

عرض المزيد
William Blair Upgrades Terns Pharma to Outperform
Analyst Upgrades

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.

GlobeNewswire

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.